JPRN-UMIN000017550已完成2 期
A phase II clinical trial (KSCC/HGCSG/CCOG/PerSeUS1501A)examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy - A phase II clinical trial (KSCC/HGCSG/CCOG/PerSeUS1501A)examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy
Kyushu Study group of Clinical Cancer0 个研究点目标入组 70 人开始时间: 2015年5月29日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)A patient who has received a transfusion, blood product, or hematopoietic growth factor such as G-CSF up to 14 days prior to enrollment 2)The patient has severe drug hypersensitivity (particularly to platinum analogs, 5-FU, or S-1) 3)The patient has peripheral neuropathy affecting the sensory nerves (Grade 1 or worse) 4)The patient has an active infection 5)The patient has poorly controlled hypertension 6)The patient has poorly controlled diabetes (patients with controlled diabetes who are receiving insulin treatment are eligible for enrollment) 7)The patient has heart disease that may pose a problem 8)The patient has severe pulmonary disease 9)he patient has a psychiatric disorder that may pose a problem or a history of central nervous system dysfunction 10)The patient has active gastrointestinal tract bleeding requiring repeated transfusions 11)The patient is receiving phenytoin, warfarin potassium,or flucytosine 12)The patient has moderate or more severe fluid accumulation in body cavities,such as pleural effusions and ascites,that continually requires treatment such as drainage 13)The patient has brain metastasis or clinical features suggesting brain metastasis 14)The patient has extensive bone metastasis (as determined by the patient's primary physician) 15)The patient has watery diarrhea (watery stool) (Grade 2 or worse) 16)The patient has active multiple cancers 17)The patient has a history of receiving platinum-based antineoplastic agents (e.g. oxaliplatin and cisplatin) 18)A woman who is pregnant, nursing, or possibly pregnant or a man who is trying to conceive with a partner 19)The patient tests positive for HBsAg or antibodies to HCV (Date of testing required) 20)A patient who is deemed to need antiviral therapyb (as of enrollment) for HBV-related hepatitis 21)A lead investigator or the patient's primary physician otherwise deems that participation in this trial is not appropriate for the patient
研究者
相似试验
招募中
2 期
Cladribine therapy in MyastheniaMyasthenia gravis2024-517083-32-00Uniwersytet Medyczny W Lublinie200
进行中（未招募）
2 期
A clinical trial of neoadjuvant taxane chemotherapy for women with locally advanced breast cancerocally advanced breast cancerLocally advanced breast cancerCancer - BreastACTRN12606000305527The Cancer Council Victoria40
进行中（未招募）
1 期
ABORL - A Phase II trial aiming to evaluate the clinical interest of ABEMACICLIB in patients with locally advanced/metastatic head and neck cancer harboring an homozygous deletion of CDKN2A, and/or an amplification of CCND1 and/or of CDK6 refractory to standards treatmentsPatients with locally advanced/metastatic head and neck cancer after failure of platinum and cetuximab or anti-EGFR-basedMedDRA version: 20.0Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004537-25-FRCentre Léon Bérard25
进行中（未招募）
2 期
ImmunoTACEHepacellular CarcinomaLiverCancerISRCTN11889464niversity of Birmingham (UK)48
进行中（未招募）
1 期
A study comparing the standard treatment of transarterial chemoembolisation (TACE)plus low doses of chemotherapy (cyclophosphamide) with an immune cell derived vaccineHepatocellular carcinomaEUCTR2011-001690-62-GBniversity of Birmingham48